Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up

source extracted confidence: high 2026-04-09
#adult #apolipoproteins #cholesterol #colestipol #coronary-artery-disease

Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up

Cashin-Hemphill et al., 1990 | JAMA | Rct

Citation

Cashin-Hemphill L, Mack W J, ... Blankenhorn D H. Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up. JAMA. 1990-Dec-19;264(23):3013-7

Abstract

The Cholesterol Lowering Atherosclerosis Study (CLAS) was a randomized, placebo-controlled, angiographic trial testing combined colestipol-niacin therapy in 162 subjects. Two-year results (CLAS-I) showed decreased atherosclerosis progression and increased regression. We now describe a subgroup of 103 subjects treated for 4 years (CLAS-II). Changes in blood lipid, lipoprotein-cholesterol, and apolipoprotein levels were maintained, and at 4 years significantly more drug-treated subjects demonstrated nonprogression (52% drug- vs 15% placebo-treated) and regression (18% drug- vs 6% placebo-treated) in native coronary artery lesions. Significantly fewer drug-treated subjects developed new lesions in native coronary arteries (14% drug- vs 40% placebo-treated) and bypass grafts (16% drug- vs 38% placebo-treated). These results confirm CLAS-I findings and indicate that regression can continue for 4 years. They reaffirm the need for early initiation of vigorous long-term lipid lowering therapy in coronary bypass subjects.

Key Findings

They reaffirm the need for early initiation of vigorous long-term lipid lowering therapy in coronary bypass subjects.

Outcomes Measured

  • Requires manual extraction

Population

Field Value
Population See abstract
Sample Size 162
Age Range See abstract
Condition See abstract

MeSH Terms

  • Adult
  • Apolipoproteins
  • Cholesterol
  • Colestipol
  • Coronary Artery Disease
  • Drug Therapy, Combination
  • Follow-Up Studies
  • Humans
  • Hypercholesterolemia
  • Lipids
  • Male
  • Middle Aged
  • Niacin
  • Radiography

Evidence Classification

  • Level: Rct
  • Publication Types: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.
  • Vertical: niacin-atherosclerosis

Provenance

  • PMID: 2243429
  • DOI: (not available)
  • PMCID: Not in PMC
  • Verified: 2026-04-09 via PubMed E-utilities API

Source extracted via PubMed E-utilities API on 2026-04-09